Chemohormonal therapy had a greater effect on biochemical progression-free survival. At three years' follow-up, 29% of patients receiving chemotherapy plus hormonal therapy remained free of rising ...
LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces the launch by its Rex MD men’s health brand of TestoRx, a new direct-to-consumer men’s hormone therapy ...